Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | WebDisclosure

Basculer en Français

9561	Companies
188864	Keywords
120595	Articles
100792	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

PRESS RELEASE

published on 09/15/2025 at 16:45, 3 months 6 days ago

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
Protagonist Therapeutics to present Phase 2b ANTHEM-UC study data on targeted oral peptide icotrokinra at UEGW Week 2025 in Berlin. Company focuses on advanced therapies in ulcerative colitis

Ulcerative Colitis Protagonist Therapeutics Icotrokinra Phase 2b ANTHEM-UC Study UEGW Week 2025
BRIEF

published on 09/11/2025 at 14:05, 3 months 10 days ago

Un acteur majeur sollicite l'approbation de l'EMA pour l'icotrokinra dans le traitement du psoriasis

Essais Cliniques Icotrokinra Psoriasis En Plaques Efficacité Du Traitement Demande D'admission À L'EMA
BRIEF

published on 09/11/2025 at 14:05, 3 months 10 days ago

Protagonist Seeks EMA Approval for Icotrokinra in Psoriasis

Clinical Trials Plaque Psoriasis Icotrokinra Treatment Efficacy EMA Application
PRESS RELEASE

published on 09/11/2025 at 14:00, 3 months 10 days ago

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
Protagonist Therapeutics submits application to EMA for first approval of icotrokinra, an investigational targeted oral peptide blocking IL-23 receptor in plaque psoriasis treatment

Protagonist Therapeutics Plaque Psoriasis Treatment IL-23 Receptor Icoktrokinra EMA Submission
BRIEF

published on 08/26/2025 at 22:10, 3 months 26 days ago

Protagonist Therapeutics Engages in Key Investment Conferences

Clinical Trials Protagonist Therapeutics Investment Conferences Biopharmaceutical Development Icotrokinra And Rusfertide
BRIEF

published on 08/26/2025 at 22:10, 3 months 26 days ago

Protagonist Therapeutics participe à des conférences d'investissement clés

Essais Cliniques Thérapeutique Protagoniste Conférences D'investissement Développement Biopharmaceutique Icotrokinra Et Rusfertide
PRESS RELEASE

published on 08/26/2025 at 22:05, 3 months 26 days ago

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
Protagonist Therapeutics announced CEO's participation in investment bank conferences in September. Company's advanced Phase 3 clinical development and future plans highlighted

Protagonist Therapeutics Phase 3 Clinical Development NDA Submission Investment Bank Conferences Drug Discovery Programs
BRIEF

published on 08/25/2025 at 13:05, 3 months 27 days ago

Le Rusfertide de Protagonist Therapeutics reçoit la désignation de thérapie révolutionnaire de la FDA

Rusfertide Thérapeutique Protagoniste Polyglobulie Vraie Thérapie Révolutionnaire Phase 3 VÉRIFIER
BRIEF

published on 08/25/2025 at 13:05, 3 months 27 days ago

Protagonist Therapeutics' Rusfertide Receives FDA Breakthrough Therapy Designation

Protagonist Therapeutics Rusfertide Polycythemia Vera Breakthrough Therapy Phase 3 VERIFY
PRESS RELEASE

published on 08/25/2025 at 13:00, 3 months 27 days ago

Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
Protagonist Therapeutics' rusfertide granted Breakthrough Therapy Designation by the FDA for polycythemia vera, complementing Orphan Drug and Fast Track designations. NDA filing on track for Q4

FDA Protagonist Therapeutics Rusfertide Breakthrough Therapy Designation NDA Filing

Accesswire

Published on 12/20/2025 at 00:30, 2 days 5 hours ago

Alphinat Announces a Profit of $120,155 for Fiscal Year Ended August 31, 2025
Published on 12/19/2025 at 22:00, 2 days 7 hours ago

GMV Minerals Inc. Closes Non-Brokered Equity Financing
Published on 12/19/2025 at 18:30, 2 days 11 hours ago

Eagle Plains Shareholders Approve all Matters at Annual General Meeting
Published on 12/19/2025 at 14:40, 2 days 15 hours ago

Northern Superior Announces Closing of the Arrangement
Published on 12/19/2025 at 13:30, 2 days 16 hours ago

Quartz Commences Trading On The OTCQX Best Market Under The Symbol QZMRF

View all ACCESSWIRE

EQS Group

Published on 12/22/2025 at 04:30, 1 hour 20 minutes ago

DFSK Officially Enters the Egyptian Market with Strategic Vehicle Lineup
Published on 12/22/2025 at 00:35, 5 hours 15 minutes ago

Samsung to Host Series of Tech Forums at CES 2026
Published on 12/22/2025 at 00:05, 5 hours 45 minutes ago

Samsung To Unveil AI Vision Built With Google Gemini at CES 2026
Published on 12/21/2025 at 08:55, 20 hours 55 minutes ago

Vantage Markets recognised for real-time threat intelligence collaboration with Trend Micro
Published on 12/20/2025 at 16:45, 1 day 13 hours ago

Shanghai Electric Powers Up Iraq's Energy Future with Major 625MW Efficiency Upgrade

Les Echos

Published on 12/19/2025 at 21:57, 2 days 7 hours ago

Mise à disposition du document d’enregistrement universel
Published on 12/19/2025 at 08:30, 2 days 21 hours ago

Share capital decrease by way of treasury shares cancellation
Published on 12/19/2025 at 08:30, 2 days 21 hours ago

Réduction du capital par voie d’annulation d’actions propres
Published on 12/19/2025 at 07:00, 2 days 22 hours ago

EURAZEO ANNONCE AVOIR MENÉ AVEC SUCCÈS UNE TRANSACTION ACCÉLÉRANT SA ROTATION D'ACTIFS
Published on 12/19/2025 at 07:00, 2 days 22 hours ago

EURAZEO ANNOUNCES A SUCCESSFUL TRANSACTION ACCELERATING ITS ASSET ROTATION

View all LES ECHOS COMFI WIRE